Literature DB >> 19616494

Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response.

Benjamin M N Kagina1, Brian Abel, Mark Bowmaker, Thomas J Scriba, Sebastian Gelderbloem, Erica Smit, Mzwandile Erasmus, Nonhlanhla Nene, Gerhard Walzl, Gillian Black, Gregory D Hussey, Anneke C Hesseling, Willem A Hanekom.   

Abstract

BACKGROUND: In most tuberculosis (TB) endemic countries, bacillus Calmette-Guérin (BCG) is usually given around birth to prevent severe TB in infants. The neonatal immune system is immature. Our hypothesis was that delaying BCG vaccination from birth to 10 weeks of age would enhance the vaccine-induced immune response.
METHODS: In a randomized clinical trial, BCG was administered intradermally either at birth (n=25) or at 10 weeks of age (n=21). Ten weeks after vaccination, and at 1 year of age, vaccine-specific CD4 and CD8 T cell responses were measured with a whole blood intracellular cytokine assay.
RESULTS: Infants who received delayed BCG vaccination demonstrated higher frequencies of BCG-specific CD4 T cells, particularly polyfunctional T cells co-expressing IFN-gamma, TNF-alpha and IL-2, and most strikingly at 1 year of age.
CONCLUSIONS: Delaying BCG vaccination from birth to 10 weeks of age enhances the quantitative and qualitative BCG-specific T cell response, when measured at 1 year of age.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19616494      PMCID: PMC2745558          DOI: 10.1016/j.vaccine.2009.06.103

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  40 in total

1.  Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis.

Authors:  A M Caruso; N Serbina; E Klein; K Triebold; B R Bloom; J L Flynn
Journal:  J Immunol       Date:  1999-05-01       Impact factor: 5.422

2.  Vaccine-induced CD8+ central memory T cells in protection from simian AIDS.

Authors:  Monica Vaccari; Christopher J Trindade; David Venzon; Maurizio Zanetti; Genoveffa Franchini
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

3.  A case-control study of protection against tuberculosis by BCG revaccination in Recife, Brazil.

Authors:  O M S Dantas; R A de A Ximenes; M de F P M de Albuquerque; N L C L da Silva; U R Montarroyos; W V de Souza; T C C Pereira; A R L Campelo; L C Rodrigues
Journal:  Int J Tuberc Lung Dis       Date:  2006-05       Impact factor: 2.373

4.  Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine.

Authors:  Patricia Gorak-Stolinska; Rosemary E Weir; Sian Floyd; Maeve K Lalor; Sally Stenson; Keith Branson; Rose Blitz; Sarah Luke; Bernadette Nazareth; Anne Ben-Smith; Paul E M Fine; Hazel M Dockrell
Journal:  Vaccine       Date:  2006-05-08       Impact factor: 3.641

5.  Protective effect of Bacillus Calmette-Guerin (BCG) vaccination in children with extra-pulmonary tuberculosis, but not the pulmonary disease. A case-control study in Rosario, Argentina.

Authors:  Elena Bonifachich; Monica Chort; Ana Astigarraga; Nora Diaz; Beatriz Brunet; Stella Maris Pezzotto; Oscar Bottasso
Journal:  Vaccine       Date:  2006-01-06       Impact factor: 3.641

6.  Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination.

Authors:  A Marchant; T Goetghebuer; M O Ota; I Wolfe; S J Ceesay; D De Groote; T Corrah; S Bennett; J Wheeler; K Huygen; P Aaby; K P McAdam; M J Newport
Journal:  J Immunol       Date:  1999-08-15       Impact factor: 5.422

7.  High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.

Authors:  Sandra Hervas-Stubbs; Laleh Majlessi; Marcela Simsova; Jana Morova; Marie-Jesus Rojas; Clémence Nouzé; Priscille Brodin; Peter Sebo; Claude Leclerc
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

8.  Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness.

Authors:  B Bourdin Trunz; Pem Fine; C Dye
Journal:  Lancet       Date:  2006-04-08       Impact factor: 79.321

9.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

Authors:  Michael R Betts; Martha C Nason; Sadie M West; Stephen C De Rosa; Stephen A Migueles; Jonathan Abraham; Michael M Lederman; Jose M Benito; Paul A Goepfert; Mark Connors; Mario Roederer; Richard A Koup
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

10.  An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.

Authors:  Laleh Majlessi; Marcela Simsova; Zdenka Jarvis; Priscille Brodin; Marie-Jésus Rojas; Cécile Bauche; Clémence Nouzé; Daniel Ladant; Stewart T Cole; Peter Sebo; Claude Leclerc
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

View more
  52 in total

Review 1.  Latent tuberculosis: what the host "sees"?

Authors:  Hannah P Gideon; JoAnne L Flynn
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

Review 2.  Tuberculosis vaccines in clinical trials.

Authors:  Rosalind Rowland; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

Review 3.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

4.  Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns.

Authors:  Andreia P Soares; Cheong K C Kwong Chung; Terry Choice; E Jane Hughes; Gail Jacobs; Esme Janse van Rensburg; Gloria Khomba; Marwou de Kock; Lesedi Lerumo; Lebohang Makhethe; Mbulelo H Maneli; Bernadette Pienaar; Erica Smit; Nontobeko G Tena-Coki; Leandre van Wyk; W Henry Boom; Gilla Kaplan; Thomas J Scriba; Willem A Hanekom
Journal:  J Infect Dis       Date:  2013-01-04       Impact factor: 5.226

Review 5.  Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.

Authors:  Alberto Cagigi; Nicola Cotugno; Carlo Giaquinto; Luciana Nicolosi; Stefania Bernardi; Paolo Rossi; Iyadh Douagi; Paolo Palma
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

6.  Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.

Authors:  Maximillian Rosario; John Fulkerson; Shamit Soneji; Joe Parker; Eung-Jun Im; Nicola Borthwick; Anne Bridgeman; Charles Bourne; Joan Joseph; Jerald C Sadoff; Tomás Hanke
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

7.  In vitro T-cell profile induced by BCG Moreau in healthy Brazilian volunteers.

Authors:  C Ponte; L Peres; S Marinho; J Lima; M Siqueira; T Pedro; P De Luca; C Cascabulho; L R Castello-Branco; P R Z Antas
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.

Authors:  Thomas J Scriba; Michele Tameris; Nazma Mansoor; Erica Smit; Linda van der Merwe; Fatima Isaacs; Alana Keyser; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Anthony Hawkridge; Adrian V S Hill; Gregory D Hussey; Hassan Mahomed; Helen McShane; Willem A Hanekom
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

9.  Pattern and determinants of BCG immunisation delays in a sub-Saharan African community.

Authors:  Bolajoko O Olusanya
Journal:  Health Res Policy Syst       Date:  2010-01-20

10.  Delayed BCG vaccination results in minimal alterations in T cell immunogenicity of acellular pertussis and tetanus immunizations in HIV-exposed infants.

Authors:  Anna K Blakney; Christophe Toukam Tchakoute; Anneke C Hesseling; Elvis B Kidzeru; Christine E Jones; Jo-Ann S Passmore; Donald L Sodora; Clive M Gray; Heather B Jaspan
Journal:  Vaccine       Date:  2015-08-07       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.